Announced details
Glaucoma treatment
Expected to extend the product life
The Company originated and developed H-1337 and is the patent holder.
Canadian application number 3120751. Patent allowed, but patent registration number and expiration date are Not disclosed
No change to the earnings forecast for the fiscal year ending December 2026
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Glaucoma treatment H-1337 |
| Relationship with the Company | The Company originated and developed H-1337 and is the patent holder. |
| Applicable area | Glaucoma treatment |
| Registration number and expiry date | Canadian application number 3120751. Patent allowed, but patent registration number and expiration date are Not disclosed |
| Quantitative Effects | Expected to extend the product life |
| Impact on Business Performance | No change to the earnings forecast for the fiscal year ending December 2026 |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Company explains that the patent forms part of its lifecycle management strategy to extend the product life of H-1337, and that securing patents in various countries will support future expansion into those markets and contribute to scaling up the product.